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BACKGROUND: No comparisons of different doses of docetaxel-capecitabine in patients with advanced gastric cancer have been
performed.
METHODS: Patients with previously untreated metastatic/locally advanced gastro-oesophageal or gastric adenocarcinoma were
enrolled in a prospective multicentre phase II trial. Two sequential cohorts received docetaxel 75mgm
 2 (day 1) plus capecitabine
1000mgm
 2 twice daily (days 1–14) (cohort I) or docetaxel 60mgm
 2 (day 1) plus capecitabine 800mgm
 2 twice daily
(days 1–14) (cohort II) every 3 weeks. The primary end point was confirmed overall response rate.
RESULTS: In all, 91 patients were enrolled (cohort I, n¼40; cohort II, n¼51) and 87 were evaluable for efficacy (n¼38, 49,
respectively). Overall response rate was 50.0% in cohort I and 23.5% in cohort II (exploratory analysis, P¼0.014). Median times to
tumour progression and overall survival were 5.6 and 10.1 months in cohort I and 3.7 and 7.2 months in cohort II, respectively. Dose
reductions for docetaxel and capecitabine were required in 50.0% and 57.5% of patients in cohort I and 11.8% and 15.7% in cohort II,
respectively.
CONCLUSION: Starting treatment with full doses and reducing promptly seems to be the more promisingly effective strategy than
starting cautiously with lower doses. Docetaxel/capecitabine 75/2000mgm
 2 is a manageable, convenient outpatient combination
with promising efficacy against advanced gastric cancer.
British Journal of Cancer (2011) 105, 505–512. doi:10.1038/bjc.2011.278 www.bjcancer.com
Published online 26 July 2011
& 2011 Cancer Research UK
Keywords: gastric cancer; capecitabine; docetaxel; dose–response
                                                              
Recent epidemiological data indicate that 0.93 million new cases of
gastric and gastro-oesophageal junction cancer are diagnosed
annually worldwide (Kamangar et al, 2006). More than 60% of
patients present with locally advanced or metastatic disease or
develop metastases after initial resection (Parkin et al, 1999). In
patients with advanced gastric cancer, chemotherapy improves
overall survival compared with best supportive care (Wagner et al,
2010), but there is no single accepted standard chemotherapy
regimen. Both cisplatin plus 5-fluorouracil (CF) (Kim et al, 1993;
Vanhoefer et al, 2000; Ohtsu et al, 2003; van Cutsem et al, 2006)
and epirubicin plus CF (ECF) (Webb et al, 1997; Ross et al, 2002)
have established efficacy and are recognised reference regimens for
comparative trials.
During the past decade, several new-generation cytotoxic agents,
including capecitabine, irinotecan, oxaliplatin and docetaxel, have
been investigated for the treatment of gastric cancer. The phase III
V325 study (van Cutsem et al, 2006) established the efficacy of
docetaxel as first-line therapy for advanced gastric cancer. The
final results showed that adding docetaxel to the CF regimen (DCF)
improved overall survival, response rate, time to disease progres-
sion and health-related quality of life, but was associated with a
marked increase in haematological toxicity. As a result, various
cooperative groups and institutions tested modified versions of the
DCF regimen in phase II studies (Park et al, 2005; Thuss-Patience
et al, 2005; Lorenzen et al, 2007; Al-Batran et al, 2008; Shah
et al, 2010; Tebbutt et al, 2010). As part of this initiative,
we demonstrated that a simplified regimen of docetaxel plus
5-fluorouracil had similar efficacy to ECF in patients
with advanced gastric cancer in a randomised phase II study
(Thuss-Patience et al, 2005), suggesting that cisplatin does not
need to be a mandatory component of an effective combination.
As our study was conducted, two phase III trials have shown
that the oral fluoropyrimidine, capecitabine, has at least equivalent
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sefficacy to infused 5-fluorouracil when given as part of a
combination regimen in patients with advanced gastric cancer
(Cunningham et al, 2008; Kang et al, 2009). Several phase II trials
have reported promising efficacy with the combination of
docetaxel and capecitabine in patients with advanced gastric
cancer (Park et al, 2004; Chun et al, 2005; Kim et al, 2005;
Lorenzen et al, 2005; Giordano et al, 2006; Rosati et al, 2007;
Lo et al, 2010; Tebbutt et al, 2010).
All approaches to optimise docetaxel–fluoropyrimidine-based
regimens focus on modifying chemotherapy dose and application.
As there are no phase IIl trials investigating this question, it is
unclear whether or not changes in chemotherapy dose affect
efficacy. To our knowledge, there has been no comparison of
different doses of docetaxel–capecitabine. Therefore, in this study
of the Arbeitsgemeinschaft Internistische Onkologie (AIO), we
examined two sequential patient cohorts treated with different
doses of docetaxel in combination with capecitabine to determine
if maximal doses are really necessary in the palliative setting or if
lower doses might have similar efficacy with better tolerability.
MATERIALS AND METHODS
Study design
This was a prospective, non-randomised, multicentre phase II trial.
Patients were recruited sequentially to two separate cohorts and
treated with different doses of docetaxel plus capecitabine; the first
40 patients received higher doses of docetaxel–capecitabine
(cohort I) and the next 51 patients received lower doses (cohort II).
After completion of cohort I, it was decided to enrich the
information gained by this trial by an amendment, lowering
the dose of chemotherapy in a similar study population. Although the
regimen tested in cohort I proved to be effective, safe and tolerable,
frequent dose reductions were necessary and Common Toxicity
Criteria (CTC) grade 1 and 2 toxicities were frequent, which were
bothersome for the patient. As the treatment setting was palliative
and benefit should be maximised by minimal side effects, an alternate
strategy was investigated. Cohort II was initiated with a dose
reduction of both drugs by 20% to investigate whether grade 1–4 side
effects can be reduced, further dose adjustments can be avoided, but
efficacy can be maintained. A reduction by 20% resulted in dose
levels for each individual drug, which were investigated previously
(Lee et al, 2008; Tebbutt et al, 2010).
The study was conducted according to the Declaration of
Helsinki, registered in www.clinicaltrials.gov (no. NCT00142038)
and the protocol was approved by the local ethics body. All
patients provided written informed consent before study entry.
Patient population
Ambulatory patients aged 18–75 years with histologically con-
firmed, locally advanced or metastatic adenocarcinoma of the
stomach or gastro-oesophageal junction were eligible. Measurable
disease was required for study inclusion. No previous chemother-
apy for advanced/metastatic disease or concurrent radiotherapy
was allowed. Patients were required to have an Eastern Coopera-
tive Oncology Group performance status of 2 or less (Karnofsky
performance index of X60%). Adequate bone marrow (leukocyte
count 43.0 10
9l
 1, platelet count 4100 10
9l
 1), renal (serum
creatinine o1.25 upper limit of normal and/or creatinine
clearance 460mlmin
 1 according to Cockroft–Gault formula)
and liver (serum bilirubin o1.5mgdl
 1, alanine aminotransferase
and aspartate aminotransferase p3 upper limit of normal)
function was required. Patients with a co-existing secondary
tumour (except basal cell carcinoma of the skin or carcinoma
in situ of the cervix), uncontrolled infection, central nervous
system metastases, recent major surgery (o2 weeks), anatomical
or inflammatory intestinal problems, or an inability to take oral
medication were excluded. The eligibility criteria for both study
cohorts were identical.
Study evaluation
At baseline, clinical investigations were performed within 8 days,
and tumour imaging within 21 days, before study inclusion. The
baseline evaluation included a physical examination, assessment of
medical history and symptoms, evaluation of performance status
and routine blood analysis (haematology and biochemistry).
During treatment, full blood count was repeated every week and
all other parameters were re-evaluated before each chemotherapy
cycle.
An electrocardiogram and abdominal computed tomography
scan were performed in all patients at baseline, with further
imaging if clinically indicated (i.e. bone scan, head computed
tomography). During treatment, imaging of target lesions and
non-target lesions was repeated every two cycles (every 6 weeks)
using the same imaging procedures as at baseline. Tumour
response was classified according to Response Evaluation Criteria
In Solid Tumours 1.0 guidelines and verified 4–6 weeks later
(Therasse et al, 2000), and evaluated by independent radiologists.
After the end of study treatment, patients were followed up every
second month until death. Toxicity was evaluated on a weekly
basis using the National Cancer Institute-CTC (Version 2.0).
Tumour-related symptoms were assessed by the treating
physician every 3 weeks on direct questioning. Symptomatic
improvement was defined as subjective improvement as stated by
the patient of at least one tumour-related symptom without
worsening of any other or appearance of any new tumour-related
symptom.
Treatment
Patients in cohort I received intravenous docetaxel 75mgm
 2 on
day 1 given as a 1-h infusion plus oral capecitabine 1000mgm
 2
twice daily on days 1–14, every 3 weeks. Patients in cohort II
received docetaxel 60mgm
 2 on day 1 and capecitabine
800mgm
 2 twice daily on days 1–14, every 3 weeks. Patients
received chemotherapy for up to a maximum of 10 cycles, or until
tumour progression or unacceptable toxicity.
Premedication with oral dexamethasone 8mg was given the
evening before day 1 of each cycle, as well as on the morning and
evening of days 1 and 2. A 5-HT3 antagonist was also
recommended on day 1. Prophylactic granulocyte-colony-stimu-
lating factor was recommended in patients older than 70 years.
Treatment in both cohorts was delivered up to the beginning of
toxicity and then interrupted or dose reduced: for grade 2
toxicities (except for isolated neutropenia/leukopenia/anaemia or
alopecia), treatment was interrupted until symptoms had resolved
to grade 0 or 1. For a second occurrence of grade 2 toxicity or a
grade 3 event, treatment was interrupted until symptoms had
resolved to grade 0 or 1 and docetaxel and capecitabine doses were
reduced by 25%. For a second occurrence of grade 3 toxicity or a
grade 4 event, treatment was interrupted until symptoms had
resolved to grade 0 or 1 and docetaxel and capecitabine doses were
reduced to 50%. Uncomplicated neutropenia/leukopenia grade 3
or 4 did not lead to dose reductions of docetaxel/capecitabine or
interruption of capecitabine as long as it resolved to grade 1 before
starting the next cycle. For grade 3/4 neutropenia/leukopenia
lasting longer than 1 week or complicated by febrile neutropenia
(body temperature X38.51C), the docetaxel dose was reduced
by 25%. Granulocyte-colony-stimulating factor was not recom-
mended as secondary prophylaxis in patients younger than
70 years.
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sStatistical analysis
The primary study end point was overall response rate, and
secondary end points were overall survival, time to tumour
progression and toxicity. Time to tumour progression was defined
as the time from study inclusion to documented progressive
disease. Overall survival was defined as the time from study
inclusion to death from any cause. Symptomatic improvement was
defined as subjective improvement of at least one tumour-related
symptom (e.g., dysphagia, weight loss, loss of appetite, pain,
abdominal fullness after meals) without worsening of any other
symptom or appearance of any new tumour-related symptom.
Kaplan–Meier methods were used to estimate time-to-event end
points. Statistical comparisons of efficacy end points between the
two patient cohorts were exploratory only. The statistical model
was not prospectively designed for this comparison.
The study was designed according to the two-stage optimum
design for phase II studies (Simon, 1989). For the null hypothesis,
it was assumed that the true response rate was less than 25%, with
an expected response rate of 45%. If at least 4 of the first 14
patients showed a response, the study was to be expanded to
44 patients. If at least 15 responses were documented in these
44 patients, the null hypothesis was rejected. This design provides
a probability of 10% of accepting a regimen with a response rate of
less than 25%, and a probability of 10% of rejecting a regimen with
a response rate of more than 45%.
When the null hypothesis was rejected after 44 included patients
(cohort I), the protocol was amended to continue with lower doses
of docetaxel and capecitabine to optimise tolerability (cohort II).
The same statistical design as for cohort I was applied for cohort II.
The study was continued to a maximum of 95 patients (including
drop outs) (see Figure 1).
RESULTS
In all, 95 patients were registered to the trial; four patients were
excluded from the analysis owing to major violations of the
inclusion criteria (see Figure 1). Therefore, a total of 91 evaluable
patients were recruited from four centres in Germany from March
2004 to December 2006 (cohort I, n¼40; cohort II, n¼51). At the
time of analysis (May 2008), 84 patients had died, six patients were
alive and one patient was lost to follow-up.
Patient baseline characteristics are presented in Table 1. Baseline
characteristics were generally well balanced between the two
cohorts, except that patients in cohort I had more tumours of the
gastro-oesophageal junction (50.0% vs 39.2% in cohort II) and
more patients with 42 metastatic sites (57.5% vs 47.1%).
Treatment exposure
The total number of chemotherapy cycles administered in cohort I
was 257 (median 6, range 1–10) and in cohort II was 247 (median
4, range 1–10). Treatment modifications were required more
frequently in cohort I than in cohort II (Table 2). Dose reductions
became necessary after a median of three cycles of full-dose
docetaxel and capecitabine in cohort I and three cycles of
capecitabine and four cycles of full-dose docetaxel in cohort II,
respectively. The total dose of chemotherapy that could be
delivered was higher in cohort I. The main reasons for dose
modifications were non-haematological toxicities. The majority of
uncomplicated neutropenia was short lasting and did not result in
a dose reduction. Calculating the planned dose of chemotherapy
for the delivered number of cycles, in cohort I 88.2% of the
planned dose of docetaxel and 83.7% of the planned dose of
capecitabine could be administered compared with 94.2% of the
planned dose of docetaxel and 92.4% of the planned dose of
capecitabine administered in cohort II. The main reason for
treatment termination was tumour progression (cohort I: 62.5%;
cohort II: 78.4%). Toxicity (cohort I: 5%; cohort II: 5.9%) or
withdrawal of consent (cohort I: 0%; cohort II: 2.0%) rarely lead to
treatment termination.
Efficacy
A summary of confirmed response rates is presented in Table 3.
Complete and partial responses were documented in 2 and 18
Registered patients
n=95
Registered in cohort I:
n=44
Registered in cohort II:
n=51
Evaluable pts.: n=40 Evaluable pts.: n=51
Drop out:
excluded: n=4*
Drop out:
none
Objective remission
Stage I optimum design:
7 of 14 pts.
Objective remission
Stage I optimum design:
6 of 14 pts.
Continuation criteria met Continuation criteria met
Objective remission
Stage II optimum design:
20 of 40 pts.
Objective remission
Stage II optimum design:
12 of 51 pts.**
Null hypothesis rejected
Continue cohort II
Null hypothesis not rejected
Figure 1 Patient flowchart. *Reasons for exclusion: no gastric cancer (n¼3) and patient gave wrong identity (n¼1). **Because there were no drop outs,
patient number exceeds that required statistically (n¼44).
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spatients in cohort I, respectively, and in 0 and 12 patients in cohort
II, respectively. The null hypothesis from the statistical design
could be rejected in cohort I, but not in cohort II (see Figure 1).
Overall response rates, the primary study end point, were 50.0%
(n¼20) in cohort I and 23.5% (n¼12) in cohort II. The study was
not powered or designed to compare the two cohorts. In an
exploratory analysis, the observed difference was statistically
significant (P¼0.014) (Fisher’s exact test, two sided).
Symptomatic improvement was evident in 27 of 37 (73.0%)
patients with baseline symptoms in cohort I and 27 of 40 (67.5%)
patients in cohort II.
Kaplan–Meier curves for time to tumour progression and
overall survival are shown in Figure 2. Median time to tumour
progression was 5.6 months (95% confidence intervals 3.9–7.3) in
cohort I and 3.7 months (95% confidence intervals (CI) 2.5–5.0) in
cohort II. Median overall survival was 10.1 months (95% CI: 7.3–
13.0) in cohort I and 7.2 months (95% CI: 4.1–10.2) in cohort II.
Exploratory statistical analysis of the observed differences in time
to tumour progression (P¼0.10, log-rank test; hazard ratio¼0.71;
95% CI: 0.47–1.08) and overall survival (P¼0.20, log-rank test;
hazard ratio¼0.75; 95% CI: 0.48–1.16) were not significant.
Safety
All patients were evaluable for safety. A summary of all adverse
events by grade is provided in Table 4. All toxicities occurred more
frequently in cohort I than in cohort II.
Non-haematological adverse events reported most frequently
with the docetaxel–capecitabine regimen were asthenia, alopecia,
nausea, hand–foot syndrome and diarrhoea. Regardless of the
doses of capecitabine and docetaxel administered, these events
were mostly mild to moderate in severity (grades 1 and 2),
and grade 3 events were manageable (Table 4). Grade 4
non-haematological events were documented in a total of four
patients: cohort I, vomiting (n¼1) and pulmonary embolism (n¼1);
Table 1 Baseline characteristics (N¼91)
Cohort I (N¼40)
Docetaxel
75mg m
 2 plus
capecitabine
1000mg m
 2 b.i.d.
Cohort II (N¼51)
Docetaxel
60mg m
 2 plus
capecitabine
800mg m
 2 b.i.d.
Median age (range), years 62 (32–79) 62 (35–77)
Sex,n(%)
Male 29 (72.5) 39 (76.4)
Female 11 (27.5) 12 (23.5)
Tumor-related symptoms,n(%) 37 (92.5) 40 (78.4)
Appetite loss 14 (35.0) 18 (35.3)
Nausea/vomiting 12 (30.0) 16 (31.4)
Weight loss 20 (50.0) 28 (54.9)
Pain 23 (57.5) 31 (60.8)
Dysphagia 11 (27.5) 11 (21.6)
Other 19 (47.5) 22 (43.1)
ECOG performance status, n (%)
0 7 (17.5) 11 (21.6)
1 27 (67.5) 30 (58.8)
2 6 (15.0) 10 (19.6)
Primary tumor,n(%)
Gastro-esophageal junction 20 (50.0) 20 (39.2)
Gastric body 13 (32.5) 25 (49.0)
Not specified 7 (17.5) 6 (11.7)
Extent of disease,n(%)
Metastatic 40 (100) 51 (100)
Locally advanced 0 (0) 0 (0)
Histological type
Intestinal 13 (32.5) 16 (31.4)
Diffuse 11 (27.5) 16 (31.4)
Not specified 16 (40.0) 19 (37.3)
Metastatic sites,n(%)
p2 17 (42.5) 27 (52.9)
42 23 (57.5) 24 (47.1)
Organs involved by metastases,n(%)
Peritoneal carcinomatosis 15 (37.5) 17 (33.3)
Lung 7 (17.5) 8 (15.7)
Lymphnode 27 (67.5) 32 (62.7)
Liver 20 (50.0) 29 (56.9)
Bone 4 (10.0) 2 (3.9)
Intra-abdominal mass
a 9 (22.5) 5 (9.8)
Abdominal wall 3 (7.5) 1 (2.0)
Other
b 6 (15.0) 2 (3.9)
Surgery for primary tumor,n(%)
Yes 21 (52.5) 30 (58.8)
No 19 (47.5) 20 (39.2)
Not known — 1 (1.9)
Measurable disease, n (%) 40 (100) 50 (98.0)
Abbreviations: b.i.d.¼twice daily; ECOG¼Eastern Cooperative Oncology Group.
aIncluding masses involving pancreas, spleen, ovary, and other intraabdominal mass
lesions.
bIncluding pleura, skin, muscle, breast.
Table 2 Treatment delivery
Cohort I
(N¼40)
Docetaxel
75mgm
 2 plus
capecitabine
1000mgm
 2
b.i.d.
Cohort II
(N¼51)
Docetaxel
60mgm
 2 plus
capecitabine
800mgm
 2
b.i.d.
Cycles delivered
In total (median/range) 6 (1–10) 4 (1–10)
With full-dose docetaxel
(median/range)
3 (1–10) 4 (1–10)
With full-dose capecitabine
(median/range)
3 (1–10) 3 (1–10)
Treatment modification
Dose reductions
Docetaxel 20 pts. (50.0%) 6 pts. (11.8%)
Capecitabine 23 pts. (57.5%) 8 pts. (15.7%)
Treatment delay 17 pts. (42.5%) 9 pts. (17.6%)
Treatment interruptions
(41 week)
16 pts. (40.0%) 7 pts. (13.7%)
Treatment exposure
Median dose delivered per patient
Docetaxel 412.5mgm
 2 240.0mgm
 2
Capecitabine 143160mgm
 2 88429mgm
 2
Median dose delivered per cycle
Docetaxel 71.3mgm
 2 60.0mgm
 2
Capecitabine 878mgm
 2 b.i.d. 800mgm
 2 b.i.d.
Received dose intensity per patient (median)
a
Docetaxel 95.1% 100%
Capecitabine 87.8% 100%
Received dose intensity per cycle
b
Docetaxel 88.2% 94.2%
Capecitabine 83.7% 92.4%
Abbreviations: b.i.d.¼twice daily; pts.¼patients.
aPlanned dose for patient compared
with delivered dose.
bPlanned dose for all cycles compared with delivered dose in all
cycles.
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scohort II, cardiac arrhythmia (n¼1) and pulmonary oedema (fluid
retention) (n¼1). One patient in cohort I died at home after the first
cycle of chemotherapy due to a pulmonary embolism (grade 5 event).
Neutropenia and leukopenia were the most frequently reported
haematological toxicity (Table 4). While both thrombocytopenia
and anaemia were generally grade 1 or 2 events, grade 3/4
neutropenia and leukopenia were common in both patient cohorts.
Grade 3 and 4 neutropenia was documented in 8 (20.0%) and 13
(32.5%) patients in cohort I, respectively, and in 4 (7.8%) and 8
(15.7%) patients in cohort II, respectively.
DISCUSSION
Several modified forms of DCF have been tested in an attempt to
improve the toxicity profile of this regimen (Park et al, 2005;
Lorenzen et al, 2007; Al-Batran et al, 2008; Shah et al, 2010;
Tebbutt et al, 2010). Only the US trial (Shah et al, 2010) included a
reference regimen as comparator and could demonstrate a
promising improvement of tolerability and efficacy by a modified
DCF. In a previous phase II study, we demonstrated that docetaxel
plus infused 5-fluorouracil had similar efficacy to the standard ECF
regimen in the first-line treatment of patients with advanced
gastric cancer (Thuss-Patience et al, 2005). As substitution of oral
capecitabine for 5-fluorouracil is now accepted in patients with
advanced gastric cancer (Cunningham et al, 2008; Kang et al,
2009), docetaxel and capecitabine is a logical combination in this
setting. Several phase II studies have tested capecitabine in
combination with docetaxel as first-line therapy in patients with
advanced gastric cancer (Park et al, 2004; Chun et al, 2005; Kim
et al, 2005; Giordano et al, 2006; Orditura et al, 2006; Tebbutt et al,
2010), but none has studied the effects of different doses.
Table 3 Confirmed response rates (RECIST)
No. patients (%)
Cohort I (N¼40)
Docetaxel
75mgm
 2 plus
capecitabine
1000mgm
 2 b.i.d.
Cohort II (N¼51)
Docetaxel
60mgm
 2 plus
capecitabine
800mgm
 2 b.i.d.
Overall response rate 20 (50.0) 12 (23.5)
P-value (Fisher’s exact test,
two sided)
0.014
Complete response 2 (5.0) 0 (0)
Partial response 18 (45.0) 12 (23.5)
Stable disease 15 (37.5) 24 (47.1)
Disease progression 3 (7.5) 13 (25.5)
Not evaluable
a 2 (5.0) 2 (3.9)
Abbreviations: b.i.d.¼twice daily; RECIST¼Response Evaluation Criteria In Solid
Tumours.
aReasons for not being evaluable: early treatment termination after one (3
pts.) or two cycles (1 pt.) due to toxicity, doctor’s decision or withdrawal of consent
with incomplete staging investigations, but without clinical signs of tumour
progression.
Median time to tumour progression:
Cohort I: 5.6 months (95% CI 3.9–7.3)
Cohort II: 3.7 months (95% CI 2.5–5.0)
P=0.10 (log-rank test)
Median overall survival:
Cohort I: 10.1 months (95% CI 7.3–13.0)
Cohort II: 7.2 months (95% CI 4.1–10.2)
P=0.20 (log-rank test)
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Figure 2 Time to tumour progression (A) and overall survival (B)i n
cohort I (higher dose, n¼40) and cohort II (lower dose, n¼51) treated
with docetaxel and capecitabine. (A) Median time to tumour progression:
cohort I, 5.6 months (95% CI: 3.9–7.3), cohort II, 3.7 months (95% CI: 2.5–
5.0), P¼0.10 (log-rank test). (B) Median overall survival: cohort I, 10.1
months (95% CI: 7.3–13.0), cohort II, 7.2 months (95% CI: 4.1–10.2),
P¼0.20 (log-rank test).
Table 4 Toxicity by grade
No. of patients (%)
Cohort I (N¼40) Cohort II (N¼51)
Docetaxel
75mgm
 2 plus
capecitabine
1000mgm
 2 b.i.d.
Docetaxel
60mgm
 2
plus capecitabine
800mgm
 2 b.i.d.
Grade
1/2
Grade
3/4
Grade
1/2
Grade
3/4
Non-haematological toxicity
Asthenia 32 (80.0) 4 (10.0) 39 (76.5) 1 (2.0)
Alopecia 33 (82.5) 0 (0) 32 (62.7) 0 (0)
Nausea 27 (67.5) 1 (2.5) 24 (47.1) 2 (3.9)
Hand–foot syndrome 17 (42.5) 8 (20.0) 18 (35.3) 4 (7.8)
Diarrhoea 18 (45.0) 6 (15.0) 16 (31.4) 5 (9.8)
Nail changes 24 (60.0) 0 (0) 13 (25.5) 0 (0)
Stomatitis 15 (37.5) 4 (10.0) 15 (29.4) 0 (0)
Paraesthesia 17 (42.5) 2 (5.0) 8 (15.7) 1 (2.0)
Vomiting 13 (32.5) 1 (2.5) 12 (23.5) 2 (3.9)
Non-neutropenic fever 14 (35.0) 1 (2.5) 14 (27.5) 3 (5.9)
Neutropenic fever 0 (0) 5 (12.5) 0 (0) 1 (2.0)
Dizziness 10 (25.0) 2 (5.0) 12 (23.5) 0 (0)
Fluid retention 8 (20.0) 1 (2.5) 6 (11.8) 1 (2.0)
Cardiac arrhythmia 1 (2.5) 2 (5.0) 1 (2.0) 2 (3.9)
Thrombosis/pulm. embolism 3 (7.5) 3 (7.5)
a 0 (0) 0 (0)
Haematological toxicity
Leukopenia 15 (37.5) 15 (37.5) 13 (25.5) 14 (27.5)
Neutropenia 3 (7.5) 21 (52.5) 9 (17.6) 12 (23.5)
Anaemia 22 (55.0) 3 (7.5) 25 (49.0) 3 (5.9)
Thrombocytopenia 10 (25.0) 0 (0) 9 (17.6) 0 (0)
Abbreviations: b.i.d.¼twice daily; CTC, Common Toxicity Criteria.
aOne of theses
patients died due to a pulmonary embolism (CTC grade 5).
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capecitabine in sequential cohorts of patients with inoperable,
locally advanced or metastatic gastric cancer. As it is not a
randomised trial, by principle some bias cannot be ruled out. To
minimise bias, consecutive patients were included. The two
cohorts had similar baseline characteristics; the mild imbalance
between gastro-oesophageal and gastric body cancer is not
expected to influence primary end points, as published previously
(Chau et al, 2009). A very promising response rate of 50.0% was
observed in patients treated with higher doses of docetaxel–
capecitabine (docetaxel 75mgm
 2 on day 1 plus capecitabine
2000mgm
 2 on days 1–14 every 3 weeks) compared with patients
treated with lower doses (23.5%). Although the study was not
designed to support a statistical comparison of the two patient
cohorts, an exploratory analysis showed that there was a
significant difference in favour of the higher dose regimen in
terms of overall response rate. Time to tumour progression and
overall survival were also both extended by approximately 2
months with the higher dose regimen compared with the lower
dose regimen. These findings are mature as nearly all events had
occurred at the time of analysis.
The toxicity profile of the docetaxel–capecitabine regimen in
our study was characterised by mild-to-moderate non-haematolo-
gical adverse events. Leukopenia/neutropenia was the most
frequent haematological adverse event; grade 3/4 events were
reported in 30–50% of patients depending on the docetaxel dose
used. This profile of events is in keeping with other phase II
studies of the docetaxel–capecitabine regimen (Park et al, 2004;
Chun et al, 2005; Kim et al, 2005). Our data suggest that
docetaxel–capecitabine at both dose levels investigated can be
given safely in an ambulatory setting without unexpected toxicity.
The lower dose regimen had an improved toxicity profile and
required fewer dose reductions. Despite more dose reductions
during the course of treatment, the higher dose regimen (cohort I)
was also tolerable. A median of three cycles could be administered
at full dose before dose reductions became necessary (Table 2).
To our knowledge, this is the first study that allows a
comparison of two dose levels of the same regimen. Starting
treatment with a higher dose of docetaxel and capecitabine is
significantly more effective than starting with a moderate dose,
even though many more dose reductions were necessary with the
higher starting dose. It is the first study showing dose-dependent
efficacy of docetaxel and capecitabine in gastric cancer.
This trial evaluates two different palliative strategies: strategy
1 – treat aggressively with a high-dose regimen and reduce doses as
necessary; or strategy 2 – start cautiously with a less aggressive
form of chemotherapy. On the basis of our findings, we suggest
that a high-dose strategy, with dose reductions as needed, is more
effective than a conservative approach. As the median age was only
62 years and only a minority of patients were 70 years and older
(cohort I, 11 patients; cohort II, 13 patients), our trial unfortu-
nately cannot answer the question whether this strategy also
applies to elderly patients. Al-Batran et al (2010) could demon-
strate that elderly patients also tolerate intense chemotherapy and
benefit which would support this strategy. Further support for high
starting doses with dose reductions as needed comes from the
study of O’Shaughnessy et al (2002) in patients with metastatic
breast cancer. In this study, it was demonstrated that the efficacy
of docetaxel–capecitabine was not compromised by dose reduc-
tions required for the management of toxicity.
An alternate strategy might be to start at lower doses and
escalate if possible. So far no data support this strategy in gastric
cancer. In our view, it seems questionable whether similarly high
treatment exposure can be achieved in the first cycles to result in
best possible efficacy, but this needs to be investigated.
Several different regimens combining capecitabine and docetax-
el have been tested in phase II trials as first-line therapy in patients
with advanced gastric cancer (Table 5). Response rates in these
studies ranged from 26 to 60%, median time to disease
progression/progression-free survival from 4.4 to 5.2 months and
median overall survival from 8.4 to 12.0 months. Lower doses of
docetaxel administered weekly seem to be less promising in terms
of efficacy compared with a 3-weekly administration. The efficacy
of our higher dose regimen is consistent with these data, whereas
our lower dose regimen is among the least active of those
described (Table 5). The rates of neutropenia reported in these
trials were highly variable, influenced by the dose and scheduling
of docetaxel (Tebbutt et al, 2010).
The patients in our study were assigned to sequential cohorts
rather than randomised to treatment. Although the baseline
characteristics of the two cohorts were generally similar, the study
should be viewed with this limitation in mind. The sample size was
determined for each cohort separately rather than for a
comparison of treatments; therefore, the statistical comparisons
in the present report are exploratory only.
In conclusion, docetaxel–capecitabine is an active first-line
regimen in patients with advanced gastric cancer, which can be
given on an outpatient basis. We propose that it may be better to
start docetaxel–capecitabine at a higher dose, with dose reduc-
tions as needed, rather than initiating therapy with lower doses to
avoid dose reductions. It is a possible hypothesis that this strategy
may be relevant for all first-line chemotherapy regimens in
patients with advanced gastric cancer, although this requires
confirmation in prospective trials.
Table 5 Phase II trials of 3-weekly docetaxel–capecitabine regimens as first-line therapy in patients with advanced gastric cancer
Dose (mgm
 2) Efficacy Grade 3/4 events (%)
Study N Docetaxel Capecitabine ORR (%)
Median PFS or TTP
(months)
Median OS
(months) Neutropenia
Febrile
neutropenia
Park et al (2004) 42 75 d1 1250 b.i.d. 60 5.2 10.5 15 7
Kim et al (2005) 32 75 d1 1000 b.i.d. 44 5.1 8.4 10 7
Giordano et al (2006) 44 75 d1 825 b.i.d. 39 4.4 9.4 78 NR
Present trial 40 75 d1 1000 b.i.d. 50 5.6 10.1 53 13
51 60 d1 800 b.i.d. 24 3.9 7.7 24 2
Chun et al (2005) 55 36 d1 and 8 1000 b.i.d. 40 4.5 12.0 36 9
Orditura et al (2006) 38 36 d1, 8 and 15 625 b.i.d. d5–18
a 21 5.4 7.7 23 2
Tebbutt et al (2010) 56 30 d1 and 8 800 b.i.d. 26 4.6 10.1 2 2
50 Modified DCF 47 5.9 11.2 10 6
Abbreviations: b.i.d.¼twice daily; DCF¼docetaxel plus cisplatin plus 5-fluorouracil; NR¼not reported; ORR¼overall response rate; OS¼overall survival; PFS¼
progression-free survival; TTP¼time to tumour progression.
aRepeated every 4 weeks.
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